📰 **Theriva Q1 Net Loss Narrows; Plans Dosing Feasibility Study Of VCN-01 In H2,2026;Stock Down **

(RTTNews) - Theriva Biologics, Inc. (TOVX), a clinical-stage company, reported financial results for the first quarter ended March 31, 2026, reflecting a narrower net loss and highlighted near-term milestones for its lead candidate VCN-01.

🔗 https://www.nasdaq.com/articles/theriva-q1-net-loss-narrows-plans-dosing-feasibility-study-vcn-01-h22026stock-down

#markets #news